** Shares of cannabis firms fall after U.S. Drug Enforcement Administration's $(DEA)$ preliminary hearing on marijuana rescheduling proposal begins
** Tilray Brands TLRY.O falls 1.1% and U.S.-listed shares of Cronos Group CRON.O falls 1.9%
** Toronto-listed shares of Canopy Growth WEED.TO falls 1.3% and Trulieve Cannabis TRUL.CD falls 0.5%
** Last week, DEA said the hearing "will serve as a procedural day to address legal and logistical issues and discuss future dates for the evidentiary hearing on the merits"; the agency said no witness testimony will be heard
** Despite marijuana being legal in dozens of U.S. states, federal law categorizes it as a schedule I drug and prohibits most conventional U.S. banks from doing business with cannabis firms
(Reporting by Pooja Menon in Bengaluru)
((Pooja.Menon@thomsonreuters.com;))
Comments